Nabriva Therapeutics (NASDAQ:NBRV)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Friday, RTT News reports. They currently have a $5.00 price objective on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 114.59% from the company’s previous close.
A number of other equities analysts have also recently weighed in on NBRV. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Nabriva Therapeutics in a report on Thursday, May 9th. ValuEngine raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 24th. Gabelli raised Nabriva Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 target price on the stock in a research note on Thursday, May 2nd. Finally, Northland Securities reissued a “buy” rating and set a $12.50 target price on shares of Nabriva Therapeutics in a research note on Thursday. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Nabriva Therapeutics has an average rating of “Buy” and a consensus price target of $7.03.
NASDAQ:NBRV traded up $0.05 during trading hours on Friday, hitting $2.33. The company had a trading volume of 15,075 shares, compared to its average volume of 447,763. The company has a current ratio of 5.55, a quick ratio of 5.55 and a debt-to-equity ratio of 0.40. The business’s 50-day moving average price is $2.33. The firm has a market capitalization of $2.06 billion, a P/E ratio of -1.44 and a beta of 2.40. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $3.27.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.04. The company had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.88 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. On average, equities analysts expect that Nabriva Therapeutics will post -1.14 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP acquired a new stake in shares of Nabriva Therapeutics in the fourth quarter valued at approximately $37,000. Jane Street Group LLC purchased a new stake in Nabriva Therapeutics in the 4th quarter valued at $29,000. FMR LLC grew its holdings in Nabriva Therapeutics by 514.2% in the 4th quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after buying an additional 1,542,700 shares in the last quarter. Fosun International Ltd purchased a new stake in Nabriva Therapeutics in the 1st quarter valued at $1,593,000. Finally, Commonwealth Equity Services LLC grew its holdings in Nabriva Therapeutics by 30.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 3.01% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: Why do analysts give a neutral rating?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.